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There is evidence that paralytic poliomyelitis occurred in ancient times, but it was not
recognized as a distinct disease until the eighteenth century and did not come into prominence
until the late nineteenth century when epidemics began to appear. Outbreaks of increasing size
were reported first in the Scandinavian countries, then in the United States and elsewhere, to the
surprise and consternation of the medical profession. Poliovirus was first isolated in 1908, but
many years of intensive research were required before the epidemiology and pathogenesis ofthe
disease were sufficiently understood to allow preventive measures to be devised. The road to
eventual success was complicated by controversies, setbacks, and tragedies, played out and
influenced by many powerful personalities. Today there are two effective vaccines. The disease
has been virtually eliminated in countries where they have been used extensively, yet in the
developing areas of the world recent "lameness surveys" indicate that the incidence of paralytic
poliomeylitis isashigh asitwasduringthepeakyears in the UnitedStates in theearly 1950s. The
challenge now is to use the available vaccines to extend control to the developing countries and
eventually to achieve elimination ofthe disease worldwide.
Physicians today arevery much awareofhow "new" and puzzling diseases suddenly
appear on the scene for in the 1970s we were surprised by legionella pneumonia, and
in the 1980s by acquired immunodeficiency syndrome (AIDS). Approximately a
hundred years ago, however, it was paralytic poliomyelitis that was the mystery. This
disease turned up in epidemic form in several European countries and in the United
States, to thecomplete bafflement ofthe medical profession. Nooneknew what caused
it, how it spread, or why there should suddenly be epidemics when for the previous 100
years it has been a curiosity seen largely as rare sporadic cases in the youngest age
group. Thestoryofhow thevarious piecesofthepuzzle were puttogether toprovide an
understanding ofthe etiology, epidemiology, and pathogenesis ofpoliomyelitis-basic
information for development of preventive measures-is a long and tortuous one,
covering the first halfofthe twentieth century. It has much to teach us about the way
scientific research moves-sometimes forward, sometimes back-and how the power-
ful personalities ofinvestigators sometimes accelerate and sometimes retard scientific
progress [1].
HISTORICAL BACKGROUND
To go back a bit in history, it seems probable that polioviruses have been around
about as long as man. The first recorded evidence oftheir capacity to induce paralytic
disease is a beautiful Egyptian steleofthe eighteenth dynasty (1580-1350 B.C.) now in
the Carlsberg Glyptotek in Copenhagen. It shows a young priest with a withered and
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shortened right leg, the foot held in the equinus position, deformities interpreted as
most probably due to paralytic poliomyelitis. There is evidence that the disease also
occurred in Greco-Roman times, but the first medical description did not come until
the eighteenth century. In 1789, Michael Underwood, a London pediatrician, included
in the second edition of his book, Treatise on Diseases ofChildren, an unmistakable
description of paralytic poliomyelitis under the heading "Debility of the Lower
Extremities." He described the limitation of its occurrence to infants and young
children, the onset with fever, and the sudden appearance of weakness of the
extremities. The clinical description was enlarged in subsequent editions; the disease
was mentioned as being not uncommon but there is no mention of epidemic
occurrence.
Underwood and those who subsequently described cases in the early nineteenth
century weregreatly puzzled about thecause oftheparalysis and the natureand siteof
the lesion. Heine, a German orthopedist, published a monograph in 1840 focusing
primarily on the long-term paralytic consequences, which he correctly concluded were
due to involvement ofthe spinal cord [2].
Although much was learned in the second half of the nineteenth century about the
clinical and pathologic aspects of the disease through the observations of Medin and
Wickman in Sweden, and Charcot and his colleagues in France, it was the sudden
appearance of epidemics that aroused even greater interest and concern around the
turn of the century. The first outbreaks occurred in Scandinavia, but in 1894 the
largest one so far recorded-132 cases-appeared in Rutland County, Vermont. In his
report Caverly noted a shift in the age incidence of cases, with adolescents and young
adults being affected as well as young children [3]. This samechange in the behaviorof
the epidemic disease was documented by Ivar Wickman who studied the 1905
epidemic (>1,000 cases) in Sweden. Wickman, in analyzing the outbreak, stressed the
contagious nature of the infection (until then an unsettled point) and also recognized
the occurrence of mild, nonparalytic cases [4]. One of the puzzling epidemiologic
features had been the usual lack of a history of contact between paralytic cases.
Wickman's meticulous investigations led him to conclude that the mild cases were as
contagious as the paralytic ones and were responsible for wide dissemination of the
agent. This was a tremendously important discovery made, remarkably, before the
discovery ofthe etiologic agent.
The outbreaks described by Caverly and by Wickman pointed up two important
features in the changing epidemiology of poliomyelitis which became increasingly
prominent over the years. First, epidemics emerged only in economically advanced
countriesoftheworldwhile in theunderdeveloped areas thedisease remainedendemic;
and, second, ever-larger outbreaks occurred (9,000 cases in New York City in 1916),
and older age groups were increasingly involved as well as children under five. The
likely explanation of these patterns is thought to be related to ways of life-to an
improved sanitary environment in industrialized countries which protected young
children from early exposure to the virus, allowing a build-up in the number of
susceptibles among whom epidemics could get under way. In contrast, in the
underdeveloped, largelytropicalcountriesoftheworld where thesanitaryenvironment
remains poor, infection and immunity develop in the first few years oflife. Thus there
are not enough susceptibles for an epidemic to occur, and cases remain confined to the
youngest age group.
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THE DISCOVERY OF THE VIRUS: EXPERIMENTS IN MONKEYS
In Vienna in 1908 Landsteiner and Popper isolated poliovirus by inoculating spinal
cord material from fatal cases intraperitoneally into monkeys [5]. The animals
developed typical paralytic poliomyelitis and the characteristic lesions of the anterior
horn cells of the cord that had been seen in humans were demonstrated. This
breakthrough caused an immediate reaction and burst of activity at the Rockefeller
Institute in New York. Epidemic poliomyelitis had already become a problem in New
York City and elsewhere in the United States, and the staff at the Rockefeller, the
leading medical research institution in the country, was ready to deal with the
challenge ofthisdevastating disease. Dr. Simon Flexner, the Director, was a towering
figure who championed scientific medicine and had already made important contribu-
tions to several infectious diseases. He immediately took on poliomyelitis with vigor
and enthusiasm. His first paper on the subject, in 1909, dealt with his finding that the
disease could be transmitted tomonkeys serially by intracerebral inoculation [6]. This
observation laid the groundwork for the extensive investigations by Flexner and his
colleagues over the next 25 years. Unfortunately, by concentrating on serial intracere-
bral passage of the MV strain ofvirus, a highly neurotropic form of the agent evolved.
Using this strain to infect monkeys by the intranasal route led to the erroneous
conclusion that, in humans, virus entered by way of the nasal passages and travelled
directly to the central nervous system via the olfactory pathway. A method of
prevention was even devised on this basis: zinc sulfate was swabbed on the nasal
mucosa ofmany children, resulting in the loss of the sense of smell in some but not in
prevention of poliomyelitis.
Flexner succeeded in convincing his colleagues that poliovirus was strictly neuro-
tropic; i.e., unable to multiply except in nervous tissue. This view became the accepted
dogma and remained so for more than 20years. Such a turn ofevents was particularly
unfortunate because as early as 1912 Swedish investigators, Kling and his associates,
had reported isolation of the virus from throat and fecal specimens of both paralytic
andnonparalytic cases [7]. Flexnerignored these findings, with the result that progress
inunderstanding theepidemiology andpathogenesis ofpoliomyelitis was delayed until
the 1930s and 1940s.
CLINICAL VIROLOGY OF POLIOVIRUS INFECTIONS
The approach that led Dr. Flexner astray was concentration on laboratory experi-
ments in monkeys, to the complete exclusion of studies involving patients. The tide did
not begin to turn until 1931 when James Trask and John Paul at Yale, faced with a
large epidemic that filled the New Haven Hospital with acute cases, decided to
undertake investigations on the clinical virology of poliomyelitis. They formed The
YalePoliomyelitis Study Unit, somehow managed to acquire $1,500, purchased a few
monkeys, andbegan work. Theirobjective was tosee iftheycould isolate the virus from
patients who had the minor illness or abortive form of the disease rather than those
with paralysis. Two of 11 throat washings from such patients seen during the 1931
epidemic yielded virus when inoculated into monkeys [8]. This was the first definite
recovery of the agent from living patients since the report of Kling et al. in 1912. It
began a new phase of poliomyelitis research. A few years later the Yale group
demonstrated the presence of the virus in the feces of a case of mild nonparalytic
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disease for up to 24 days after onset. These findings were soon confirmed by others,
and, not surprisingly, virus was also recovered from sewage [9]. The gathering
laboratory evidence thatpoliomyelitis isprimarily an enteric infection and that mild or
inapparent infections are just as infectious as paralytic cases proved at last the
correctness of Wickman's 1905 interpretation based on his epidemiologic observa-
tions.
By theearly 1940s the thesis thatpoliovirus is strictly neurotropic and travels via the
olfactory pathway to the central nervous system was no longer tenable. Sabin and
Ward had conclusively demonstrated that in fatal human cases no involvement of the
olfactory bulbs was present, but virus was recovered from the alimentary tract,
primarily from the pharyngeal wall and the ileum, as well as from the nervous system
[10].
PATHOGENESIS
Recognition that primary infection with poliovirus takes place in the alimentary
tract stimulated renewed interest in the pathogenesis of the disease. It was generally
agreed that the oropharynx is the portal of entry, and the major site of primary virus
multiplication is in the ileum. But how does the virus travel to the central nervous
system? Invasion via the blood seemed a likely possibility, but attempts over the years
todemonstrate viremia inmonkeys and in the course ofthe human disease had yielded
largely negative results. The reason became apparent when it was shown that, by the
time the patient is hospitalized with paralysis, antibodies are already present in the
serum and it is too late to detect circulating virus. By examining the blood of orally
infectedmonkeys andchimpanzeesearly in the incubation period, it was finally shown
in 1952 thatviremia occursregularly[11]. This samepattern was then found in human
infections by testing the blood of contacts of paralytic cases who were still in the
incubation period, or wereexperiencing the minor illness or even inapparent infection,
and had not yetdeveloped antibodies [12,13]. These findings were very exciting at the
time, for they indicated that a likely route ofinvasion ofthe central nervous system is
through the bloodstream. There is also evidence, however, from the experimental
disease and human infections, that under certain circumstances the pathway travelled
by the virus is via autonomic nerve fiber endings in the alimentary tract to motor
neurons of the brain and spinal cord [14].
Thecomplexities ofthepathogenesis ofpoliovirus infections are still not completely
understood. Thesignificance ofdemonstration ofthe regular occurrence ofviremia lay
in the implication that if antibodies could be induced by vaccines, viremia would not
occur, invasion of the central nervous system would be blocked, and paralytic
poliomyelitis could be prevented. Thus the discovery of viremia provided a surge of
optimism about the potential ofvaccines for control of the disease.
ANTIGENIC TYPES OF POLIOVIRUS AND SEROEPIDEMIOLOGY
Investigations in the 1930s and 1940s also focused on immunologic responses to
infection and to serologic surveys of normal persons. At first these were hampered by
thenecessity to usemonkeys in neutralization tests, a cumbersome, expensive, and not
entirely reliable technique. Another difficulty which led to confusing results was that
in earlier work it had been assumed that there was only one strain of poliovirus,
although in theearly 1930s, Burnet and Macnamara had demonstrated that there were
at least twodistinctvirustypes [15]. Thisobservation wasofextreme importance, forif
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a vaccine were ever to be developed it would have to protect against all strains to be
generally useful. In recognition ofthis fundamental point, a large collaborative typing
program was set up in 1948 by the National Foundation for Infantile Paralysis. The
results, reported in 1951, indicated that the 100 isolates tested fell into only three
distinct antigenic types [16].
Another large step forward had been made by Dr. Charles Armstrong who, at the
National Institutes ofHealth, succeeded in adapting the Lansing strain ofvirus (later
identified as Type II) first to cotton rats and then to mice [17]. As a result, quantitative
neutralization tests on large numbers of sera could be readily performed. The
mouse-adapted strain was used extensively in the 1940s in serologic surveys in the
United States, and during World War II in Africa, the Far East, and elsewhere. The
results ofsuch surveys provided important insights into the epidemiology ofpoliovirus
infections. In a study conducted in Egypt, Paul et al. demonstrated that Type II
poliovirus infections were highly endemic: 80 percent of children living in Egyptian
villages had acquired Type II antibodies by two years of age, and close to 100 percent
by the age offour years [18]. These findings explained the dearth ofcases in Egyptian
adults, and pointed to the large reservoirofcirculatingvirus which served asa sourceof
infection for susceptible immigrants: e.g., American soldiers, who had high attack
rates of poliomyelitis when stationed in Egypt during World War II, far higher than
comparable troops stationed in the United States.
Perhaps the most telling use ofserologic epidemiology was the surveycarried out by
Paul et al. in 1950 in an Arctic Eskimovillage [19]. Thefindings indicated that a single
subclinical infection with poliovirus resulted in immunity which could persist for more
than 40 years. Such remoteArcticareaswith small populationgroupscould notsustain
continued circulation of the virus; it therefore disappeared when the supply of
susceptibles was exhausted. TheType II antibody patterns revealed that some 20 years
earlier this type had made its way through the population, infecting virtually all
persons alive at that time; however, no one born since had Type II antibodies. Later,
similar reconstruction ofType I and Type III activity indicated that only those over 35
were seropositive for Type I and over 45 for Type III. The implications of these
findings were of immense importance, for they suggested that if an attenuated live
poliovirus vaccine could bedeveloped, it might induce lasting immunitycomparable to
that achieved by natural infection, but without the risk ofparalysis.
GROWTH OF POLIOVIRUS IN TISSUE CULTURE AND
DEVELOPMENT OF VACCINES
The great German pathologist Virchow is quoted as saying of scientific research
"Die Methode ist Alles." The long road leading to an understanding of poliomyelitis
and eventually to its control has many examples of the truth of this dictum but none
more dramatic than the demonstration that poliovirus could be grown in cultures of
human cells derived from non-nervous tissue [20]. This discovery by Enders, Weller,
and Robbins, reported in Science in January of 1949, had a far-reaching impact not
only on poliovirus research, but on the whole field ofvirology, and in addition on cell
biology, genetics, and immunology.
The 1949 Science paper dealt with the growth of the Lansing (Type II) strain of
poliovirus in human embryonic cells. In a series ofpapers over the ensuing two tothree
years, the Harvard group described propagation of all three types ofpoliovirus in cell
cultures from various embryonic and postnatal organs. They also demonstrated that
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the virus damaged the cells and produced a characteristic "cytopathogenic effect"
easily visible on microscopic examination; this effect served as a marker to indicate
presence of the virus. Thus tissue culture could supplant monkey inoculation as a
method ofdetecting poliovirus in specimens from patients and in serologic tests. This
was an enormous step forward.
Ofgreatestimportance, however, wasthecontribution that thegrowthofthevirus in
tissue culture made toward making possible the development of vaccines against
poliomyelitis. In 1954 Enders, Weller, and Robbins received The Nobel Prize in
Medicine in recognition oftheir signal accomplishment.
Early Attempts to Develop a Poliovirus Vaccine
Recovery of the etiologic agent of a disease immediately conjures up dreams of
developing a vaccine to prevent the infection. This was as true in 1908 when
Landsteiner reported the isolation ofpoliovirus as it is today, when the identification of
HTLV3 as the probable cause ofAIDS has burst on the horizon. In 1911 Flexner, who
had been hard at work on poliovirus for a year and a half, was reported in The New
York Times to have said that within six months a specificremedy would beannounced,
for the way to prevent the disease had already been discovered in his laboratory [1].
Such optimism was sadly misplaced, as subsequent events proved: it was to be 44 years
before the first successful vaccine was launched by Salk and his colleagues in 1955.
There had been a number of previous attempts to immunize experimental animals,
however, beginning as early as 1910. Serial infection with small amounts oflive virus
or of virus partially inactivated by various physical and chemical methods was used.
The test of successful immunization was resistance of the monkeys to intracerebral
challenge with large amounts of virulent virus. Some success was achieved, but the
results were often erratic.
In the early 1930s, Dr. Maurice Brodie, working with Dr. W.H. Park at the New
YorkCity Health Laboratory, devised aneffective methodofinactivating poliovirus by
treatment with formalin. Using such material they succeeded in immunizing 20
monkeys. They then moved on to test the vaccine in 12 children who responded with
rises in neutralizingantibody; a few months latertheyboldly set out to immunize 3,000
children. At about the same time, in Philadelphia, Dr. John Kolmer attempted to
produce a live attenuated poliovirus vaccine by exposing suspensions of infected
monkey spinal cord to sodium ricineolate, which he claimed would partially inactivate
the virus. This preparation was distributed to the medical profession and was given to
thousands ofchildren.
The ultimate result of both the Brodie-Park and the Kolmer vaccine trials was
disaster. At least 12 cases ofparalyticpoliomyelitis (sixofthem fatal) occurred among
those given the Kolmer vaccine, and apparently some cases were also attributable to
the Brodie-Park formalin-treated material. Considering the crudeness ofthe prepara-
tions, the non-quantitative methods used, and the failure to recognize that antigeni-
callydifferent typesofpoliovirus existed, all ofthese factors made the whole enterprise
decidedly premature. The two major proponents, Brodie and Kolmer, were vigorously
denounced at several national medical meetings by such powerful voices as thoseofDr.
Thomas Rivers of the Rockefeller Institute and Dr. James Leake of the U.S. Public
Health Service. Kolmer turned to other subjects and managed to survive the storm,
but, for Brodie, a promising career fell in ruins. He died several years later, allegedly
by his own hand [1]. Ironically, he had been on the right track, for it was formalin
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treatment that eventually was used in the inactivated virus vaccine of Salk. And
Kolmer's idea ofattenuating but not killing the virus proved a fruitful approach years
later when Sabin succeeded in attenuating the three virus types and producing the oral
vaccine.
One of the most unfortunate effects of the vaccine trials of the 1930s was that they
left such a cloud over the whole subject that for 15 years no respectable investigator
would even thinkofa vaccine. But, by the early 1950s, when so much had been learned
about the pathogenesis and immune mechanisms of the infection, when the three
antigenic types were known, and the advent oftissue culture-grown virus circumvented
the necessity for using monkey central nervous system as a substrate for growing the
virus, the climate had gradually changed: thedevelopmentofa vaccineseemed feasible
after all, and work started in several laboratories.
The Inactivated (Salk) Vaccine
Dr. Jonas Salk, at the University ofPittsburgh, first worked on poliovirus during the
collaborative typing program of 1948. He was already a highly respected young
investigator as a result of his work on influenza with Dr. Thomas Francis at The
University of Michigan. During World War II, as a member of the Commission on
Influenza of the Armed Forces Epidemiologic Board (headed by Dr. Francis), he had
been intimately involved in the successful influenza immunization program. With his
knowledge ofinfluenza vaccine as a background, Salk was in a strong position to apply
the lessons learned to the development ofa similar type ofvaccine against poliomyeli-
tis. Accordingly, using tissue culture-grownvirus, theoptimum conditions for inactiva-
tion of the agent by formalin were determined and a killed poliovirus vaccine was
prepared. It proved immunogenic in animals, and when inoculated into susceptible
humans satisfactory levels of antibodies were induced after several spaced doses [21].
The ultimate test of the safety and efficacy of the vaccine came in 1954, with the
famous Francis trial, a mammoth undertaking [22]. Its director, Dr. Thomas Francis,
laid down stringent conditions for a scientifically sound program which involved two
groups of controls, one placebo-inoculated, and the other "observed." In all, some
1,800,000 children from various parts of the country, all in grades one and three,
participated. When analysis of the vast amount of serological and statistical data was
completed the results were presented at a meeting in Ann Arbor, Michigan, on April
12, 1955, the anniversary of Franklin Roosevelt's death. The event, staged by the
National Foundation for Infantile Paralysis, had many features of a Hollywood
extravaganza-features that were far from pleasing to the scientific community.
Nevertheless, the important point was that the vaccine had indeed proved successful,
giving a protective rate of greater than 50 percent. Furthermore, there had been no
evidence of any untoward effects in vaccinees. The announcement was greeted with
great relief and enthusiasm by scientists, the public, and, not least, by the press. The
vaccine was immediately licensed-that very afternoon.
Calamitous events that followed several weeks later put a decided pall on the
program. Large stockpiles of the vaccine were released immediately after licensure,
and within ten days cases of poliomyelitis began to appear in recipients. In all, there
were 260 vaccine-associated cases, 94 among vaccinated children and 166 in family
and other contacts. Almost 75 percent of the cases were paralytic; 11 patients died.
Vaccination was halted until the nature of the problem could be identified. It turned
out that the lots containing live virus could be traced to a few produced by one
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manufacturer. No cases followed use of the vaccines of other producers, but it was
nonetheless anextremely anxious period for, by the time the first cases appeared, some
four million children had already been inoculated.
Once theproblem with theoffending vaccine lots had been identified and corrected,
the immunization program went forward speedily. A minimum of three doses over a
six-month period was recommended. The potency of the vaccine and therefore its
effectiveness was increased and between the years 1955 and 1960, paralytic poliomy-
elitis in the United States fell from close to 20,000 cases per year to approximately
2,500.
Live Attenuated (Sabin) Vaccine
By 1952, several investigators had shown that the virulence of polioviruses could be
modified by laboratory manipulation. By passage in cotton rats, Koprowski had
already produced an attenuated TypeII Lansing strain that induced antibodies in
volunteers [23]. More important, Enders et al. found that serial passage in tissue
culture resulted in attenuation of a virulent Type I strain [24]. Sabin was quick to
capitalize on this observation and rapidly began an all-out attack on the problem.
While Koprowski and Cox at Lederle Laboratories also went on to develop attenuated
strains in tissue culture that were used in trials in various parts of the world, it was
Sabin who dominated the field, and whose strains were eventually the ones that were
licensed for use.
Sabin had been a highly productive investigator in the poliovirus field from the time
he first met the disease on the wards of Bellevue Hospital in New York in 1931. His
many contributions toward the elucidation of the nature of the infection and the
pathogenesis of the disease constituted a rich background from which to pursue the
difficult task of developing a safe and effective live-virus vaccine.
It was evident from experimental work and from the field studies that naturally
occurring polioviruses differ greatly in their paralytogenic capacity. The goal was
therefore to derive strains of the three virus types that had greatly reduced neuroviru-
lence but nevertheless resulted in infection ofthe alimentary tract and development of
serologic and local mucosal immunity. To identify the most avirulent preparations of
the three virus types, Sabin used individual poliovirus particles from artificially
manipulated or naturally occurring attenuated strains which were defined by their
behavior on intraspinal inoculation ofcynomolgus monkeys, the most sensitive test for
the neurotropism of the virus [25]. Those with the lowest residual neurovirulence and
thegreateststability on multiplication in thechimpanzee intestinal tract were selected
for inclusion in the vaccine. The process required 21/2 years and involved some 9,000
monkeys and 150 chimpanzees [25]. By 1956 the first tests in small numbers of
volunteers who were given the virus orally had proved successful in that intestinal
infection wasrapidly induced and was followedby brisk immune responses. There was,
however, considerable dismay when it was shown that the virus excreted by vaccinees
wasslightly more neurovirulent than that ingested. For Sabin this was something of a
dilemma but, afterdiscussing theproblem with various colleagues, the decision was to
go forward cautiously with trials in humans conducted by various investigators in the
United States and abroad-first in institutions, then among families, and gradually in
increasingly larger populationgroups [1]. The results established the immunogenicity
ofthevaccine, itssafety, and itscapacitytospread tosusceptiblecontacts ofrecipients,
thus increasing the immunization rate.
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An important development beginning in 1956 was the collaboration between Sabin
and investigators in the Soviet Union, where poliomyelitis epidemics were emerging as
a serious problem [25]. Chumakov and Voroshilova, and Smorodintsev and their
associates, using seed virus provided by Sabin, prepared large quantities ofvaccineand
proceeded to use it on an increasing scale. By 1959, when as a WHO consultant I had
theopportunity to visit the USSR and review poliovirusvaccine programs under way in
several of the republics, close to 15,000,000 children had already received the oral
vaccine (OPV). It was clear that the trials had been carefully carried out, and the
results were monitored meticulously in the laboratory and in the field. By mid-1960
approximately 100 million persons in the Soviet Union, Czechoslovakia, and East
Germany had received the Sabin strains. The result was a dramatic drop in paralytic
cases. Of great importance was the demonstration that the vaccine was safe, not only
for the recipients, but for the large numbers of unvaccinated susceptibles who must
have been exposed as contacts of vaccinees. The USSR experience was crucial in
leading to eventual acceptance of the oral vaccine in the United States as a safe and
effective product.
By the end of 1961 there had been increasingly large and successful trials ofOPV in
the United States, and rapid mass vaccine programs had been demonstrated to be
effective in terminating epidemics in Japan, Israel, Chile, and elsewhere. Finally, after
prolonged comparative testing of the candidate strains, the Sabin strains proved to be
the most attenuated, and in 1961-62 they were approved for licensure in the United
States.
Sabin's recommendation that in the beginning OPV should be administered
community-wide was adopted enthusiastically throughout the country. So-called
"Sabin Sundays" were organized in many cities by health departments and local
medical societies. They were well publicized and proved highly successful in reaching
the public. Between 1962 and 1964 some 100 million doses of the oral vaccine were
given in the United States. OPV was also incorporated into the routine vaccination
program for young children, and as its use increased there was a further striking
decline in the attack rates of paralytic poliomyelitis-from 2,600 per hundred million
in the period 1956 and 1960 when only IPV (inactivated poliovirusvaccine) was used,
to four per hundred million after 1973 when OPV had largely supplanted IPV [25]. In
1984 only four cases of poliomyelitis were reported in the U.S. population of 230
million. The success of OPV has been remarkable considering that, until recently,
immunization rates in the United States have been far from optimal: only 60 to 70
percent ofchildren received the recommended three doses.
Two problems have been encountered in the use of OPV. One is the occurrence of
possible vaccine-associated paralytic cases in vaccinees and their contacts. Since all
poliovirus strains mutate during multiplication in the human intestinal tract, the
vaccine has no doubt been causally related to someofthecases, but this is anextremely
rare event. During the period 1972-1983 the Centers for Disease Control of the U.S.
Public Health Service reported a rate of one case per 8.7 million doses distributed for
vaccine recipients, and one per 5.1 million for contacts.
The second problem with OPV has been the less than optimal immune responses in
children living in tropical areas where the sanitary environment is conducive to the
continual circulation of many enteric viruses. That this difficulty can be surmounted
by yearly mass vaccine administration to all children under four years has been amply
demonstrated in several tropical countries including Cuba, Brazil, and the Dominican
Republic [25].
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THE NATIONAL FOUNDATION FOR INFANTILE PARALYSIS
Thestoryofpoliomyelitis isincomplete without mention oftheuniqueroleplayed by
theNational Foundation forInfantileParalysis insupporting research onthediseasein
the United States, and in development ofthe two vaccines. The organization began as
The President's Birthday Ball Commission, which was established in 1933 shortly after
Franklin Roosevelt took office, and was replaced in 1938 by the National Foundation
for Infantile Paralysis (NFIP) with Basil O'Connor, a former law partner of Franklin
Roosevelt, as president. O'Connor was a highly successful, powerful, and dedicated
man. He devoted himself unstintingly to the cause of poliomyelitis and, with his
extraordinary administrative skills, built the Foundation into a national organization
which raised some twenty-five million dollars annually. The funds were used for two
principal purposes: to fund medical care for every patient with poliomyelitis, and to
support research on various aspects ofthe disease, including its prevention.
As far as research wasconcerned, the Foundation's support was critical, for its came
well before the time when the NIH was in a position to provide research grants on a
large scale. In thedevelopment ofthe twovaccines, which made thesubsequent control
of poliomyelitis possible, the NFIP was a major force, supporting the work of both
Sabin and Salk, and many other investigators in the field. As has been characteristic of
the history of poliomyelitis, however, the road was far from smooth. There were
spirited-sometimes bitter-disagreements on scientific matters with the Foundation
leaders pitted against members of its scientific advisory groups [1]. Basil O'Connor
and Dr. Thomas Rivers, president and scientific director of the NFIP, respectively,
were both aggressive and outspoken men. They concluded in the late 1950s that the
success ofthe Salk vaccine was such that there was no need to go forward with the live
attenuated-virus vaccine. But Sabin, also an aggressive and outspoken man, was not to
be deterred. He persevered undaunted, and numerous small oralvaccinetrialsusing his
strains were carried out successfully in the U.S. and elsewhere. Encouragement came
in 1957 when the World Health Organization Expert Committee on Poliomyelitis
recommended that field trials of increasing size be continued. By 1961 many millions
of persons had received OPV. Sabin proposed that in order to break the chain of
transmission of wild polioviruses, there should be rapid mass immunization programs
in which OPV would be given to persons ofall age groups regardless ofthe number of
doses of IPV previously received. The National Foundation was vigorously opposed to
this, as was the U.S. Public Health Service. On advice from a specially appointed
committee, however, the American Medical Association approved the recommenda-
tion in June of 1961 [25]. At this time OPV had not yet been licensed. But the medical
community and the American public were ready when the Sabin strains were finally
approved for use in late 1961 and early 1962.
POLIOMYELITIS IN THE 1980s
Remarkable control ofparalytic poliomyelitis has been achieved in countries which
have used either IPV or OPV extensively. OPV has beenadministered morewidely and
accounts for the general striking reduction in the incidence of the disease in the
industrialized world. In three countries, Sweden, Finland, and Holland, where only
IPV has been used and close to 100 percent of the population has been immunized,
virtual elimination ofthe indigenous infection has also been achieved. Theseresults are
indeed gratifying. Unfortunately a very different and disturbing picture in the
developing countries has come to light as a result of recent "lameness surveys."
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Because in third-world countries few cases ofpoliomyelitis are reported and epidemics
do not occur, it has been assumed that the wide dissemination of the virus resulted in
immunizing infections in the first years of life at a price of only rare paralytic cases.
This assessment proved false when surveys of school children in a number of tropical
countries revealed that the prevalence of residual paralysis characteristic of poliomy-
elitis was surprisingly high [26]. Estimates based on the findings suggested incidence
rates comparable to those during the peak years in the United States before the
introduction ofvaccine in 1955.
Several approaches to the continuing poliomyelitis problem in the developing
countries have been proposed in addition to the vigorous ongoing World Health
Organization Programme on Immunization. One advocated by Sabin involves the
country-wide administration ofOPV to all children under four years ofage each year,
on two days, two months apart. This approach has been shown to be highly effective
[25]: saturation of the childhood population with attenuated-vaccine virus displaces
virulent polioviruses and, in addition, continued circulation of the attenuated strains
increases immunization through contact infection if ingestion of the vaccine failed to
induce a "take." Such programs present many administrative and logistic problems;
they require cooperation at many levels of government and enthusiastic community
participation. Another approach has been proposed by Salk. As a result ofwork at the
Rijks Institut in Holland a killed-virus vaccine of greatly improved immunogenicity
has been developed [27]. In tropical countries, twospaced injections ofthis preparation
have proved effective in inducing satisfactory antibody responses in young children
[28]. Incorporation of the vaccine into a routine DPT vaccination program would
therefore be an appropriate means of increasing coverage; however, cost and the need
to inject the vaccine are drawbacks in third-world areas.
The recent resurgence ofinterest in poliomyelitis prompted theconvening in 1983 of
an International Symposium on Poliomyelitis Control, sponsored by the Fogarty
International Centerofthe National Institutes ofHealth, and other agencies [29]. The
agenda covered aspects ofthe accomplishments ofthe past and the problems presented
by the disease today. The prospects for better vaccines as a result ofrapid advances in
the molecular virologyofthe agentprovide anoptimistic note for thelong term. But, as
stressed by Robbins in summarizing the proceedings, the tools are currently available
for the virtual elimination of the paralytic disease even though it is unlikely that
polioviruses can be eradicated [30]. The decision as to how such improved control is to
be accomplished and which of the two vaccines is to be used will differ in various
countries, depending on many factors including local circumstances, cost, availability
ofpersonnel, and technical support systems. Thechallenge is to try to assure that every
child in every country receives one or the other vaccine.
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